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Abstract
Background: Hereditary myoclonus dystonia is often due to changes in the SGCE gene. Dystonia (DYT)-SGCE has a variable phenotype that can involve focal or
generalized myoclonus and various forms of task-specific, segmental, or generalized dystonia. Psychiatric comorbidities are common.
Case Report: We report a case of a young woman with generalized myoclonus, dystonia, and intellectual disability. She was found to have a novel SGCE splice
site variant.
Discussion: This novel variant is very likely pathogenic by in silico analysis and has not been previously reported. Additionally, her intellectual disability may
constitute a novel phenotype for patients with SGCE variants.
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Introduction
Hereditary myoclonus dystonia associated with SGCE variants was
first reported in 2001.1 The phenotypic spectrum of this condition is
broad, but most commonly features myoclonus of the upper trunk
and arms, along with cervical or brachial dystonia.2 Isolated lower
limb dystonia with myoclonus emerging years later has also been
described.3 Classically, handwriting will exacerbate arm dystonia, and
arm and cervical myoclonus.4 In many cases the myoclonus is alcohol
responsive. Variants in the SGCE gene are estimated to be responsible
for 30–50% of myoclonus dystonia syndromes,1 but variants in RELN,5
ANO3,6 TOR1A,7 and the locus for DYT158 have been reported
to have similar phenotypes. DYT-SGCE has been reported with
psychiatric comorbidities such as anxiety and obsessive compulsive
disorder.9–11 The condition can be managed medically with a variety
of agents including valproate, leviteracetam,12 clonazepam, tetrabe-
nazine,13 and sodium oxybate.14 Pallidal deep brain stimulation has
been shown to provide benefit for some patients as well.15–19 Cogni-
tive profiles of patients with DYT-SGCE are varied among reports.
Some describe no abnormalities in cognition.9,10,20 Others have indi-
cated above-average verbal intellectual functioning with impairments
in free recall and executive functioning.21,22 Frank intellectual disability
has not been previously described in these patients. Here we report a
patient with a novel SGCE variant and a history of intellectual disability.
Case report
A 21-year-old female presented to our clinic with a history of gener-
alized myoclonus since childhood with developmental delay and intel-
lectual disability. She was the product of an uneventful pregnancy and
was delivered by C-section due to fetal distress. She had Apgar scores
of 8 and 9 at 5 and 10 minutes of life, respectively, an unremarkable
postnatal course, and was able to be discharged home on her third day
of life. Whole-body occasional jerking with preservation of conscious-
ness was noted at about 1 year. Her jerking seemed to worsen with
activity. She had delayed gross and fine motor milestones (sitting at
9 months, walking at 19 months, difficulty running). She was originally
assessed by two local child neurologists; a definitive diagnosis was not
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reached after a work-up that included a normal magnetic resonance
imaging (MRI) brain scan and normal electroencephalogram although
a provisional diagnosis of cerebral palsy was entertained. At age 10,
she was administered the Wechsler Intelligence Scale for children,
fourth edition.23 Performance on that assessment showed a full-scale
intelligence quotient of 74 with deficiencies in perceptual reasoning,
working memory, and processing speed (see Supplementary Figure 1).
She graduated from a high school special education program and
enrolled in a few community college courses with special accommoda-
tions. Over the intervening years, her myoclonus worsened in severity
and began to interfere with handwriting and other daily activities, and
she would occasionally fall. It was not known if the jerking lessened
with alcohol consumption. There were reports of abnormal arm post-
uring during writing but no other complaints of neck or leg cramping,
stiffness, or posturing. She also had a history of Restless Leg Syndrome
(RLS) and generalized anxiety. Previous treatment with topiramate
and clonazepam had been ineffective at controlling movement. Family
history was significant for jerky movements in her father and paternal
grandfather, who were both intellectually normal. The proband’s brother
had been previously diagnosed with Sydenham’s chorea (see Figure 1).
Clinical examination was notable for global hypotonia, moderate gene-
ralized spontaneous myoclonus that worsened with activity, mild cervical
dystonia, and writer’s cramp (see Video 1). The Unified Myoclonus
Rating Scale24 was administered with a total score of 99 (see Supplementary
Figure 2). Her father was also noted to have milder generalized myoclonus
during her initial office visit.
MRI of the brain with a 1.5-T Siemens scanner was normal.
A dystonia comprehensive sequencing panel was carried out by Invitae
Laboratories and showed a novel, likely pathogenic variant in SGCE,
c.825+1_825+2delGT (NM_003919.2). This test was performed
using next-generation sequencing, and deletion/duplication analysis
was performed on the same assay utilizing an in-house algorithm that
determines the copy number at each target. The variants identified
through next-generation sequencing were subsequently confirmed via
appropriate methods, including, in this case, Sanger sequencing. This
2-base pair deletion at the consensus donor splice site is expected to
disrupt RNA splicing and likely results in an absent or disrupted
protein product with an ’Human Splicing Finder (HSF) score of 3.0
and Combined Annotation Dependent Depletion (CADD) prediction
score of 27.6.25,26 This variant is absent from population databases
Video 1. Video of Neurological Exam. Mild cervical dystonia with left turn.
Myoclonus affecting the neck and trunk. Myoclonus is elicited by auditory and
tactile stimuli and worsened in the trunk and arms with posture and intention. The
gait is slightly wide based and appears hypotonic. Handwriting induces worsening
of cervical dystonia and neck and truncal myoclonus. Myoclonus affects
handwriting and water pouring.
Figure 1. Pedigree. The proband has 2 male siblings, one of which was diagnosed with Syndenham chorea but has declined genetic testing. The proband’s father
has mild generalized myoclonus and was found to have the same mutation. His father was reportedly ‘jerky’ but is now deceased.
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(gnomAD27) and has not been previously reported in individuals with
SGCE-related disease. Testing of her father revealed the same variant.
The family does not have contact with the father’s extended family.
Her mother and siblings have not consented to genetic testing as yet.
Owing to the presence of intellectual disability, a whole-genome array
comparative genomic hybridization with single-nucleotide polymor-
phism (SNP) analysis from GeneDx was performed and failed to
show any abnormalities. This test is performed on a custom-designed
oligonucleotide microarray (GenomeDx v5) and the design is based on
human genome build GRCh37/UCSChg19 and contains approxi-
mately 118,000 probes that provide copy number data and 66,000
probes that generate genotype information through analysis of SNPs.
A repeat neuropsychological evaluation was performed and showed
deficits, including abstract reasoning, working memory, receptive
and expressive language, and executive functioning in the setting of
anxiety with intact short-term memory, and delayed visual recall (see
Supplementary Figure 3). She was initially treated with higher doses of
clonazepam but was limited by somnolence. Leviteracetam was also
trialed but failed to control her myoclonus adequately. She has undergone
bilateral pallidal deep brain stimulation and, at her last follow up two
months postoperatively, has demonstrated reduction in myoclonus.
Discussion
Hereditary myoclonus dystonia associated with SGCE variants was
first reported in 2001.1 There are a wide variety of clinical presenta-
tions and genetic changes that have been reported in association with
the phenotype.1,5,6,8,28 Most variants have no reported abnormalities
in cognition.9,10 Others have indicated above-average verbal intel-
lectual functioning with impairments in free recall and executive
functioning.20,22 This family illustrates the well-documented variability
in penetrance and phenotypic expression that is thought to be due to
maternal imprinting.1,29 The proband illustrates a novel phenotype that
includes intellectual disability. We do not think it likely that her birth
history contributed to her intellectual disability given her Apgar scores,
reported lack of encephalopathy after birth, and normal brain MRI. With
these items she would not meet criteria for hypoxic ischemic encephalo-
pathy or cerebral palsy. We attempted to rule out other genetic causes
of intellectual disability with a SNP array panel but acknowledge the
limitation of this approach. The significance of this variant is predicted to
by highly pathogenic given its location by in silico programs; however, we
did not attempt to determine the effect of this variant on the RNA level.
In conclusion, we describe a case of DYT-SGCE due to a novel
SGCE variant. In light of the novel phenotype herein decribed, clinicians
should not discount the possibility of an SGCE variant in a patient
who otherwise exhibits compatible signs. Such patients may benefit from
similar medical management or pallidal deep brain stimulation,15–18 and
continued attention to psychiatric comorbidities that have been described
in patients with other SGCE variant.
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